Tag - BLU

Markets

Research Capital downgrades Bellus Health on valuation, financing

Research Capital downgraded Bellus Health (NASDAQ:BLU) to “hold” from “speculative buy” and removed its previous $14.50 price target so “we can properly account for the new dilution” from a $153-million offering of new...

July 14, 2022

Developments

BELLUS Health doses first patient in Phase 2b chronic cough trial

BELLUS Health (NASDAQ:BLU; TSX:BLU) dosed the first patient in its Phase 2b study evaluating BLU-5937 for the treatment of refractory chronic cough. The study, called SOOTHE, will evaluate three doses of BLU-5937 in...

December 8, 2020

Developments

BELLUS Health enrolls first patient in Phase 2 chronic cough trial

BELLUS Health (TSX:BLU) enrolled the first patient in its Phase 2 study of BLU-5937 for the treatment of chronic cough. The study, called RELIEF, will assess the efficacy, safety, and tolerability of BLU-5937 at four...

July 31, 2019

Tag - BLU

Research Capital downgrades Bellus Health on valuation, financing

BELLUS Health doses first patient in Phase 2b chronic cough trial

BELLUS Health enrolls first patient in Phase 2 chronic cough trial

General

More